Drugs / vobramitamab duocarmazine
vobramitamab duocarmazine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05293496 | Apr 2022 → Jun 2025 | castration-resistant prostate carcinoma, hepatocellular carcinoma, malignant epithelial tumor of ovary, melanoma +2 | MacroGenics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03729596 | Nov 2018 → Mar 2023 | head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma, prostate carcinoma +1 | MacroGenics | Terminated | No outcome recorded Stop: Business |
| Phase 22 trials | ||||||
| Phase 2 | NCT06227546 | Apr 2024 → Mar 2025 overdue | small cell lung carcinoma | Georgetown University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05551117 | Jun 2023 → Jul 2024 | anal carcinoma, castration-resistant prostate carcinoma, hormone-resistant prostate carcinoma, laryngeal squamous cell carcinoma +4 | MacroGenics | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 11
| Date | Issuer | Release |
|---|---|---|
| 2026-05-13 | MacroGenics | Results MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation macrogenics.com ↗
Based on an assessment of results from the high-grade serous and platinum-resistant ovarian cancer (PROC) cohort of the LINNET study, the predetermined response rate was not achieved, and the Company no longer intends to pursue development in this indication. |
| 2025-03-20 | MacroGenics | Results MacroGenics Provides Update on Corporate Progress and 2024 Financial Results macrogenics.com ↗ |
| 2024-09-15 | MacroGenics | Results MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024 macrogenics.com ↗
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today presented updated efficacy and safety results from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, for patients with metastatic castration-resistant prostate cancer (mCRPC). |
| 2024-05-09 | MacroGenics | Results MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data macrogenics.com ↗
“We are very encouraged by the interim updated safety and preliminary efficacy data from the TAMARACK study of vobra duo in metastatic castration-resistant prostate cancer," said Scott Koenig , M.D., Ph.D., President and CEO of MacroGenics . |
| 2024-04-03 | MacroGenics | Results MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures macrogenics.com ↗
At this early data cut, pts have received a median of 3 (range 1 to 7) cycles of vobra duo; treatment is ongoing in 156 (85.7%). |
| 2021-09-16 | MacroGenics | Results MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress macrogenics.com ↗
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced preliminary safety and anti-tumor activity data from dose expansion cohorts of the Company’s ongoing Phase 1 clinical trial of MGC018. |
| 2021-05-19 | MacroGenics | Results MacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting macrogenics.com ↗
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced preliminary safety and anti-tumor activity data from the Company’s ongoing Phase 1 clinical trial of MGC018. |
| 2021-04-10 | MacroGenics | Results MacroGenics Announces Presentations at the 2021 AACR Annual Meeting macrogenics.com ↗
At clinically relevant dose levels, MGC018 demonstrated potent antitumor activity in vivo in mouse patient-derived xenograft (PDX) models of squamous cell carcinoma of the head and neck (SCCHN). |
| 2020-09-23 | MacroGenics | Results MacroGenics Announces MGC018 Publication in Molecular Cancer Therapeutics macrogenics.com ↗ |
| 2020-06-22 | MacroGenics | Results MacroGenics Announces Presentation of Preclinical Data at the 2020 AACR Annual Meeting macrogenics.com ↗
Furthermore, MGC018 combined with an anti-PD-1 antibody enhanced anti-tumor activity observed in this study. |
| 2020-05-13 | MacroGenics | Results MacroGenics Announces Preliminary Clinical Results from MGD013 and MGC018 to be Presented at the ASCO Annual Meeting macrogenics.com ↗
MacroGenics Announces Preliminary Clinical Results from MGD013 and MGC018 to be Presented at the ASCO Annual Meeting |
All press releases naming this drug 13 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vobramitamab duocarmazine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05293496 ↗ |
| Known as | AEX4089DC1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594576 ↗ |
| Known as | MGC018 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06227546 ↗ |
| Known as | Vobramitamab duocarmazina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594576 ↗ |
| Modality | Other / unclassified | “Anti-B7H3 antibody drug conjugate” NCT03729596 ↗ |
| Route | Intravenous | “0.5 mg/kg IV every 3 weeks” NCT03729596 ↗ |